Literature DB >> 11356938

In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats.

B C Ponnappa1, I Dey, G C Tu , F Zhou, M Aini, Q N Cao , Y Israel.   

Abstract

Kupffer cells play an important role in the pathogenesis of liver diseases. During endotoxemia and alcohol-induced liver disease, tissue injury is preceded by an excessive release of cytokines by these macrophages. Tumor necrosis factor-alpha (TNF-alpha) is one of the key cytokines associated with liver injury. Pre-exposure of animals to TNF-alpha antibodies has been shown to prevent macrophage-mediated liver injury in experimental animals. In this article, we describe a method to encapsulate in pH-sensitive liposomes and to deliver an antisense phosphorothioate oligonucleotide (TJU-2755) against TNF-alpha. We describe the efficacy of this formulation in inhibiting endotoxin-mediated production of TNF-alpha. The liposomes prepared were stable for over 4 weeks at pH 7.4, but readily released their contents when exposed to an acidic environment below pH 6, similar to the pH that exists in early endosomes. Male Sprague-Dawley rats were administered (i.v.) liposome-encapsulated TJU-2755 (1-2 mg/kg body wt.). Empty liposomes served as controls. Forty-eight hours postinjection, the animals were administered a single dose of lipopolysaccharide (50 microg/kg body wt.) and were sacrificed 90 min later. The TNF-alpha produced by excised liver incubated ex vivo and the levels of plasma TNF-alpha were determined. After a single administration of liposome-encapsulated antisense TJU-2755, a 30% reduction in TNF-alpha produced by liver slices was observed. Two daily doses of the antisense oligonucleotide inhibited TNF-alpha production by 50%. This was associated with a 65 to 70% reduction in plasma levels of TNF-alpha, compared with controls. These results indicate that oligonucleotide TJU-2755 encapsulated in pH-sensitive liposomes can be used to effectively reduce endotoxin-mediated production of TNF-alpha in macrophages in vivo and thus may be of value in attenuating or preventing macrophage-mediated liver injury.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356938

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Dicer-substrate siRNA inhibits tumor necrosis factor alpha secretion in Kupffer cells in vitro: in vivo targeting of Kupffer cells by siRNA-liposomes.

Authors:  Sivakamasundari Pichu; Swapna Krishnamoorthy; Bi Zhang; Yawu Jing; Andrei Shishkov; Biddanda C Ponnappa
Journal:  Pharmacol Res       Date:  2011-09-10       Impact factor: 7.658

2.  Hepatic artery infusion of antisense oligodeoxynucleotide and lipiodol mixture transfect liver cancer in rats.

Authors:  Han-Ping Wu; Gan-Sheng Feng; Yuan Tian
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

Review 3.  Nanoparticle approaches against bacterial infections.

Authors:  Weiwei Gao; Soracha Thamphiwatana; Pavimol Angsantikul; Liangfang Zhang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-07-15

Review 4.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

Review 5.  Molecular therapy for hepatic injury and fibrosis: where are we?

Authors:  Colette C Prosser; Roy D Yen; Jian Wu
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

6.  Inhibition of tumor necrosis factor alpha secretion in rat Kupffer cells by siRNA: in vivo efficacy of siRNA-liposomes.

Authors:  Yawu Jing; Andrei Shishkov; Biddanda C Ponnappa
Journal:  Biochim Biophys Acta       Date:  2007-10-02

Review 7.  Therapeutic interventions in sepsis: current and anticipated pharmacological agents.

Authors:  Prashant Shukla; G Madhava Rao; Gitu Pandey; Shweta Sharma; Naresh Mittapelly; Ranjita Shegokar; Prabhat Ranjan Mishra
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 8.  Innovations in oligonucleotide drug delivery.

Authors:  Melanie A Lysik; Susanna Wu-Pong
Journal:  J Pharm Sci       Date:  2003-08       Impact factor: 3.534

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.